Rennes Cedex

• A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting
  2022-500967-11-00 5 2023-07-06 Previously Untreated Metastatic or Unresectable Melanoma
• Evaluation of diagnostic performances of 18F-FDOPA PET KInetics as biomarkers for the improvement of care of MRI Non-contrast enhanced Gliom … Recruiting
  2022-501688-42-00 5 2023-05-24 Low Grade Glioma
• EDEN : Etude de désescalade thérapeutique et d'évaluation du marqueur miRNA M371 pour les séminomes de stade IIa/IIb < 3 cm Recruiting
  2024-514636-25-00 4 2023-05-04 Stage IIa/IIb < 3 cm seminoma
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 4 2023-01-25 ER positive HER2 negative breast cancer
• A multicenter phase 1/2 study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas Recruiting
  2024-514826-22-00 7 2022-12-05 Part A: Patients with advanced solid tumors or lymphomas.
• Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting
  2024-511884-27-00 3 2022-11-09 CD205+ve recurrent and/or metastatic tumor types including but not lim
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib … Recruiting
  2022-503068-34-00 4 2022-04-06 Metastatic Gastrointestinal Stromal Tumor
• A phase I study of the mesothelin x cd47 antibody NI-1801, as single agent and in combination with anti-pd-1 antibody, or with paclitaxel al … Recruiting
  2024-517752-35-00 1 2022-04-04 Advanced, metastatic, or recurrent solid mesothelin-expressing maligna
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cance … Recruiting
  2024-515344-23-00 4 2021-06-17 local advenced pancreatic adenocarcinoma
• AGADIR : Atezolizumab combined with EIK10001 (BDB001) and Immunogenic Radiotherapy in Patients with Advanced Solid Tumors Recruiting
  2023-509492-16-00 4 2021-03-30 Adult participants with metastatic (advanced) solid tumors.
• Interest of peri operative CHemotherapy In patients with CINSARC highrisk localized Soft Tissue Sarcoma. Recruiting
  2024-515384-62-00 5 2020-10-09 Soft Tissue Sarcoma
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 4 2019-05-07 Locally Advanced/Metastatic Urothelial Cancer
• Randomised trial evaluating mifamurtide in combination with standard chemotherapy in patients with high-grade osteosarcoma at high risk of r … Recruiting
  2024-514780-26-00 4 2018-10-23 Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting
  2023-506987-15-00 9 2016-11-17 Metastatic Castration-Resistant Prostate Cancer
• Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index Recruiting
  2024-515432-71-00 5 2016-09-13 gastrointestinal stromal tumor
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting
  2023-506027-29-00 5 2014-10-01 Children, adolescents and adults with newly diagnosed diffuse intrinsi
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris … Ended recruitment
  2023-508827-10-00 4 2025-10-13 Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
• Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Ended recruitment
  2024-517868-33-00 4 2025-06-12 NECTIN4 Amplified Advanced Breast Cancer
• A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced … Ended recruitment
  2024-512504-19-00 1 2025-05-28 solid tumors
• Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC Ended recruitment
  2024-516063-89-00 5 2025-04-10 Metastatic Pancreatic Ductal Adenocarcinoma
• A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL C … Ended recruitment
  2024-514032-25-00 4 2024-12-11 Patients with a histilogically confirmed diagnosis of cervical squamou

Showing 121–144 of 253 trials